Origene_Jan2021_ProperAntibodyDesignKeeps - 25

UltraMAB ®

The Ultra Specific IHC Antibodies
Validated against >17,000 human antigens

HER2

Specificity
Validated by
High-Density
Protein Array

UltraMAB = Minimal Cross Reactivity
Through the use of high-density protein microarray technology
developed by OriGene, our team is working to provide a new generation
of monoclonal antibodies for use in IHC evaluation and pathology.

Learn more from
our YouTube video

UltraMAB® monoclonal antibodies are the industry's only
specificity-verified reagents that have been validated against >17,000
human protein antigens. The unprecedented specificity test ensures the
minimal cross-reactivity of UltraMAB.
UltraMABs currently available HER2, ALK, β-Catenin, P53, ERCC1, Keratin8, Ki-67, etc.

The products preseted on this page are intended for research purposes only. These products are not intended to be used for therapeutic or diagnostic purpose in humans or animals.
UltraMAB® is a registered trademark of OriGene Technologies, Inc. 2020

http://www.origene.com/ultramab

Origene_Jan2021_ProperAntibodyDesignKeeps

Table of Contents for the Digital Edition of Origene_Jan2021_ProperAntibodyDesignKeeps